Status:
UNKNOWN
Neuroinflammatory PET Imaging in Autoimmune Encephalomyelitis
Lead Sponsor:
Ruijin Hospital
Conditions:
Autoimmune Encephalomyelitis
Eligibility:
All Genders
16-80 years
Phase:
NA
Brief Summary
Autoimmune encephalomyelitis is a heterogeneous group of central nervous system (CNS) autoimmune diseases characterized by the production of anti-neuron-associated autoantibodies which target neuronal...
Eligibility Criteria
Inclusion
- Experimental group:
- Inclusion criteria:
- Patients with onset for less than 2 years
- Serum autoantibody positive
- cognitive impairment or movement disorder diagnosed by two or more certified specialists.
- Exclusion criteria:
- Patients who do not meet the clinical、laboratory and imaging criteria of immune-related cognitive and movement disorders
- Medical history of surgery, trauma, stroke, tumor in brain or spine cord
- Alcoholism or drug dependence (addiction)
- Patients with pregnancy
- Healthy Volunteers group:
- Inclusion criteria:
- able to understand the purpose of clinical research and test plan
- In the brain and spine cord MR assessment, it is judged as "normal"
- Exclusion criteria:
- Any major mental illness; history of schizophrenia or schizoaffective disorder
- Any important neurological disease, such as cerebrovascular disease, inflammation or infectious disease, demyelinating disease, neurodegenerative disease, trauma in brain or spine cord
- History of alcohol or drug abuse/dependence
- Medical history of cardiac and lung disease, tumors, blood disease, poorly controlled chronic diseases
- Patients with pregnancy
Exclusion
Key Trial Info
Start Date :
December 14 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05293405
Start Date
December 14 2021
End Date
December 31 2024
Last Update
April 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ruijin Hospital
Shanghai, China, 200025